AbbVie Inc. (NYSE:ABBV) shares are edging higher Friday morning following Thursday’s announcement of positive Phase 3 trial results for its menstrual migraine treatment, atogepant. Here’s what investors need to know.
AbbVie stock is trading at elevated levels. Where are ABBV shares going?
Atogepant Meets All Endpoints in Phase 3 LUNA Trial
AbbVie announced positive topline results Thursday from its pivotal Phase 3 LUNA trial evaluating atogepant (marketed as QULIPTA/AQUIPTA) for the preventive treatment of menstrual migraine in adult patients. The study evaluated an intermittent 7-day dosing schedule per cycle, meeting its primary endpoint and all eight ranked secondary endpoints with high statistical significance.
Atogepant reduced perimenstrual migraine days by an average of 1.20 days compared to 0.40 days for placebo, representing a net 0.80-day reduction, while demonstrating meaningful improvements in acute medication use, headache burden, cognitive function, and functional disability.
